Supplemental material
Scandinavian Journal of Rheumatology
Volume 52, 2023 - Issue 5
Articles/Brief Reports
Real-world registry-based study on apremilast use in psoriasis and psoriatic arthritis in Finland
, 
, , , , , & show all
J Ruotsalainen3 Real-world Evidence and Research Services, Oriola Finland Ltd, Espoo, FinlandCorrespondence[email protected]
https://orcid.org/0000-0003-1056-3838View further author information
https://orcid.org/0000-0003-1056-3838View further author information, S Kurki3 Real-world Evidence and Research Services, Oriola Finland Ltd, Espoo, Finlandhttps://orcid.org/0000-0002-6102-0369View further author information
https://orcid.org/0000-0002-6102-0369View further author information, P Lakkakorpi4 Medical Department, Amgen AB, Espoo, Finlandhttps://orcid.org/0000-0001-9429-6495View further author information
https://orcid.org/0000-0001-9429-6495View further author information, , L Pirilä1 Centre for Rheumatology and Clinical Immunology, Division of Medicine, Turku University Hospital, Turku, Finland;2 Department of Medicine, University of Turku, Turku, Finlandhttps://orcid.org/0000-0002-4276-7344View further author information
https://orcid.org/0000-0002-4276-7344View further author information, R Harvima5 Departments of Dermatology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finlandhttps://orcid.org/0000-0002-0076-9093View further author information
https://orcid.org/0000-0002-0076-9093View further author information & A Palomäki1 Centre for Rheumatology and Clinical Immunology, Division of Medicine, Turku University Hospital, Turku, Finland;2 Department of Medicine, University of Turku, Turku, Finlandhttps://orcid.org/0000-0002-8835-8116View further author information
https://orcid.org/0000-0002-8835-8116View further author information show all